APOBEC3B mRNA Expression in Breast Cancer Correlates with Genomic Mutational Signatures

Breast cancer remains one of the most significant causes of death from disease worldwide, a reality that persists despite improvements in how doctors screen for it and treat it. To understand why some tumors behave the way they do, scientists often look at the genetic code inside the cells. Within this code, tiny errors called mutations can accumulate over time, acting like typos in a long instruction manual. Some of these typos follow a specific pattern: a letter in the genetic sequence that should be a C is changed to a T. This specific type of error is known as a mutational signature, and it is found in roughly one-third to one-half of all breast cancer cases. The biological engine behind this pattern is a family of enzymes called APOBEC, which normally function to protect the body against viruses. However, in cancer, a specific member of this family, known as APOBEC3B, often becomes overactive. When it is, it introduces these characteristic C-to-T changes into the tumor's DNA. While scientists have long known that this enzyme exists in these tumors, the full picture of how its activity relates to the tumor's behavior, its specific genetic makeup, and how it might affect a patient's response to treatment has remained incomplete.

Researchers set out to fill these gaps by examining a vast collection of data from thousands of breast cancer tumors. They looked at two different types of information for each sample: the actual DNA mutations present in the tumor and the amount of APOBEC3B messenger RNA, which serves as a measure of how much of the enzyme the tumor cells were producing. By comparing these two datasets across different types of breast cancer, the team discovered a strong link. More than 64 percent of the tumors that showed the distinct genetic pattern of APOBEC activity also had high levels of the APOBEC3B enzyme itself. This connection was statistically significant, suggesting that when the enzyme is abundant, it is indeed driving the specific genetic errors seen in the tumor.

The study went further to see what else happens inside these high-enzyme tumors. The researchers analyzed the biological pathways that were active or inactive in these cells, sorting the results by the different subtypes of breast cancer. They found that tumors with high levels of APOBEC3B showed a distinct shift in how they handled drugs. Specifically, the genes responsible for producing certain enzymes that convert the common breast cancer drug tamoxifen into its active form were turned down. These enzymes, which include CYP2D6 and CYP3A, are essential for the body to process the medication correctly. When they are less active, the drug may not work as intended, which could explain why some patients with high APOBEC3B levels do not respond well to standard hormone therapy.

At the same time, the researchers noticed a different kind of change in these same tumors. The genes involved in the metabolism of pyrimidine, a building block of DNA and RNA, were also reduced. This included genes such as IMPDH1, NME1, TK1, and DPYS. This finding suggests a double-edged sword for the cancer cells. While the reduced activity of drug-processing enzymes might make standard treatments less effective, the altered way these cells handle pyrimidine could make them more vulnerable to a different kind of attack. The authors propose that this metabolic shift creates a specific weakness that could be targeted by chemotherapy drugs based on pyrimidine.

The work does not claim to have solved the problem of breast cancer treatment, but it does offer a clearer map of the terrain. It connects the presence of a specific enzyme to a specific genetic signature and, crucially, links that combination to real changes in how the tumor processes medicine and nutrients. The findings suggest that measuring the level of APOBEC3B in a patient's tumor could help doctors predict whether the cancer might resist standard hormone therapy or, conversely, whether it might be susceptible to specific chemotherapy strategies. By understanding these metabolic dependencies, the hope is that treatment can be tailored more precisely, potentially improving outcomes for specific groups of patients who currently face difficult challenges with standard care.